Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for a limited time post-event. Merus focuses on developing innovative full-length multispecific antibodies, known as Biclonics^®, which demonstrate features similar to conventional human monoclonal antibodies, including a long half-life and low immunogenicity.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics™), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 3:30 p.m. ET.

A live webcast of the presentation will be available on the Investors and Media page of the Company's website, http://www.merus.nl. A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics^®. Biclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV. 

Investor and Media Inquiries:
Jillian Connell
Merus N.V.
Investor Relations and Corporate Communications
617-955-4716

FAQ

What is the date and time of Merus N.V.'s presentation at the Jefferies Virtual Healthcare Conference?

Merus N.V. will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET.

Who is the CEO of Merus N.V. participating in the Jefferies Virtual Healthcare Conference?

Bill Lundberg, M.D., is the CEO of Merus N.V. participating in the conference.

Where can I watch the webcast of Merus N.V.'s conference presentation?

The live webcast of Merus N.V.'s presentation will be available on the Investors and Media page of their website.

What are Biclonics developed by Merus N.V.?

Biclonics^® are innovative full-length multispecific antibodies developed by Merus N.V., exhibiting features similar to conventional human monoclonal antibodies.

How can I access the replay of Merus N.V.'s presentation after the event?

A replay of Merus N.V.'s presentation will be archived and available on their website for a limited time after the event.